Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Table 1 Comparison of clinical manifestations between patients with AML in low and high BDH2 expression groups ^a

Variables	Total (n = 113)	Low *BDH2,* expression, (n = 57)	High *BDH2,* expression, (n = 56)	P
Sex^b	113	57	56	0.467
Male	64	23	26
Female	49	34	30
Age (years)^c	54.5 (21–86)	48 (22–86)	57 (21–85)	0.193
Laboratory data^c
WBC, ìL⁻¹	30,830	37,615	24,370 (600–243,290)	0.452
WBC, ìL⁻¹	(300–296,300)	(300–216,820)	24,370 (600–243,290)	0.452
Hb, g/dL	8.3	8.3	8.4	0.365
Hb, g/dL	(4.2–15.6)	(4.4–14.3)	(4.2–15.6)	0.365
Platelet, ×1,000/ìL	42	44.5	41	0.582
Platelet, ×1,000/ìL	(3–369)	(4–175)	(3–369)	0.582
Blast, ìL⁻¹	20,188.5	13,074.15	26,001	0.172
Blast, ìL⁻¹	(0–287,411)	(126–145,572.7)	(0–287,411)	0.172
Blast in BM, %	74.8% (24.8%–97.4%)	70.8% (24.8%–94.7%)	79% (27.2%–94.4%)	0.424
CD34 (+) in BM, %	31.1%	29.5%	33.25% (0%–99.5%)	0.272
CD34 (+) in BM, %	(0%–99.9%)	(0%–99.9%)	33.25% (0%–99.5%)	0.272
FAB^b
M0	3	1 (1.75%)	2 (2.44%)	0.057
M1	28	8 (13.89%)	20 (43.90%)
M2	47	25 (47.23%)	22 (34.15%)
M3	0	0 (0%)	0 (0%)
M4	23	15 (23.61%)	9 (14.63%)
M5	7	6 (9.72%)	1 (0%)
M6	0	0 (0%)	0 (0%)
M7	4	2 (2.78%)	2 (4.88%)
Undetermined	0	0 (0%)	0 (0%)
Induction response^bd
CR	61 (70.93%)	37 (80.42%)^f	24 (60%)^g	0.032*
PR and Refractory		32	20
Induction death		1	0
Reach CR time^e
	38 ± 38.0	40.5 ± 44.3	36 ± 29.7	0.526

^aThe median value of BDH2 expression in the total population was used as the cutoff level of 9.006 to define low- and high-expression groups.
^bNumber of patients (%).
^cMedian (range).
^dOnly the 86 patients who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in the analyses.
^ePatients received conventional intensive induction chemotherapy and achieved CR, median, days ± S.D.
^fOnly 46 patients received I3A7.
^gOnly 40 patients received I3A7 (Idarubicin and Ara-C).
*Statistically significant (P < 0.05).

ISSN: 1423-0127